[Special Stock] IMBDX, Early Cancer Detection by Blood Test... Attractive Screening Cost of 1 Million Won

Cancer liquid biopsy specialist IMBDX is showing strong performance.

As of 9:58 AM on the 18th, IMBDX is trading at 13,710 KRW, up 10.92% from the previous day.

Oh Byung-yong, a researcher at Hanyang Securities, explained, "When testing for cancer, tissue biopsy, CT, MRI, and endoscopy are usually used," adding, "these methods have drawbacks such as inconvenience, high cost, and time consumption." He continued, "Recently, technology that accurately diagnoses cancer using only blood (liquid biopsy) is becoming a trend," and added, "IMBDX is a leading Korean company in this field."

He stated, "IMBDX has CancerFind, an early screening product that can diagnose 8 types of cancer, including pancreatic and liver cancer, from the early stages using blood," emphasizing, "The potential of ‘CancerFind,’ which targets the general population rather than specific patients, appears considerable."

Researcher Oh analyzed, "CancerFind uses AI to comprehensively analyze minute amounts of cancer DNA, methylation, and copy number in the blood to determine the presence of cancer," noting, "The average cancer screening accuracy (sensitivity) is 86%, and the accuracy of predicting cancer location reaches 84%." He added, "Although the cost is somewhat high at around 1 million KRW, it will be a very attractive option for the elderly who are highly interested in health and want early cancer screening."

He said, "CancerFind was launched in November last year," expressing expectations that "although it is not yet being promoted, the ripple effect when it becomes known to the public will be significant."

This content was produced with the assistance of AI translation services.